MEDS$1.68-8.20%
DataMeds AI, Inc.
Sector: Wholesale-Drugs, Proprietaries & Druggists' SundriesIndustry: Medical - DistributionCountry: USExchange: Nasdaq
Mkt Cap:$7.59M
Float & O/S:
Inst Own:
DilutionScan read 31 of DataMeds AI, Inc.'s SEC filings and found 7 warrant series, 6 convertibles, 1 equity line, 1 shelf registration, 4 S-1 registrations and 18 completed offerings on file for MEDS. The latest dilution event on file is an offering on Oct 13, 2026. Analysis updated Oct 26, 2026.
Signal8 Summary
MEDS
Near-insolvent micro-cap burning cash
Snapshot
DataMEDS AI is a tiny, cash-strapped micro-cap health IT and pharmacy company. Revenue grew 28.7% to $23.3M in FY 2025, but gross margin turned negative (-41.3%), meaning each sale loses money before other costs.
What's Happening Right Now
- : On Sep 8, 2026, DataMEDS and Tollo Health partnered with the NFL Alumni Association to roll out a telehealth and pharmacy-access campaign for rural communities through the Health Lives Here app.
- : On Aug 17, 2026, DataMEDS reported Q2 2026 revenue of $1.779M (up 14% sequentially), disclosed a $6.5M funding round, a completed 1-for-50 reverse split to address delisting risk, and a meme coin token distribution to shareholders.
- : On Aug 12, 2026, DataMEDS said its Corexa Pharmacy division stabilized at over $600,000 in July 2026 revenue and completed integration of its online store, adding GLP-1 drug offerings.
- : On Jul 29, 2026, DataMEDS expanded its blockchain data-licensing agreement with Datavault AI, extending its PharmacyChain technology beyond pharmaceutical distribution into broader healthcare and wellness data monetization.
- : On Jun 26, 2026, the company was renamed DataMeds AI, Inc. from Wellgistics Health, reflecting a pivot toward a vertically integrated data, pharmacy, and telemedicine model.
